Form 4: Assembly Biosciences CEO Jason Okazaki Reports Stock Transactions

CEO Jason Okazaki of Assembly Biosciences reports acquisition and disposition of company stock related to vesting of restricted stock units and covering tax obligations.

Summary

• On April 29, 2024, Jason Okazaki, CEO and President of Assembly Biosciences, acquired 4,166 shares of common stock due to the vesting of a performance-based restricted stock unit award.
• On April 30, 2024, Okazaki sold 1,569 shares of common stock at a weighted average price of $12.7068 to cover tax withholding obligations related to the vesting of the restricted stock units.
• Following these transactions, Okazaki beneficially owns 16,423 shares of Assembly Biosciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports routine stock transactions related to executive compensation and tax obligations. It doesn't inherently indicate positive or negative performance.

Positives

• The vesting of restricted stock units suggests that performance goals were met, which could be viewed positively.

Negatives

• The sale of shares, even if for tax purposes, could be perceived negatively by some investors, although it's a standard practice.

Risks

• There are no specific risks mentioned in this document, as it primarily details stock transactions.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into insider transactions, allowing investors to monitor the buying and selling activities of company executives and directors.

Comparison to Industry Standards

• Similar transactions are common among executives in publicly traded companies, especially in the biotechnology sector where stock-based compensation is prevalent.
• The 'sell-to-cover' practice is a standard mechanism to manage tax obligations associated with equity compensation, aligning with practices seen at companies like Gilead Sciences or Vertex Pharmaceuticals.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the 'sell-to-cover' is a common practice and unlikely to cause significant concern.

Key Dates